Biogen Idec’s ELOCTATE and ALPROLIX will grow the hemophilia market, a ZoomRx study finds
August 26, Cambridge, MA
Biogen Idec’s (NASDAQ: BIIB) new drugs for hemophilia, ELOCTATE (rFVIIIFc) and ALPROLIX (rFIXFc), are poised to capture a significant share of the hemophilia market and also grow the market steadily by increasing prophylactic treatment, a new market research study by ZoomRx reveals. ELOCTATE and ALPROLIX, indicated for hemophilia A and hemophilia B respectively, are both long-acting therapies that will significantly improve the quality of life of patients by reducing the number of infusions that patients require to manage this chronic condition.
ZoomRx, a healthcare market research consultancy, conducted this study with over 150 hemophilia treating physicians during June and July of 2013. The study reveals that physicians who treat hemophilia perceive ELOCTATE and ALPROLIX to have similar efficacy and safety profiles as the existing therapies in the market, but expect them to perform better in terms of patient convenience. With improved convenience, physicians indicate that patients are more likely to switch to a prophylactic treatment regimen, where they use the drug regularly in a preventive manner instead of using the drug only when a bleed occurs. Patients using prophylactic treatment consume significantly larger unit volumes of the drug, hence contributing to market growth, the study notes.
It is to be noted that, earlier this year, FDA accepted for review Biogen Idec’s Biologics License Applications for both ELOCTATE and ALPROLIX and these therapies are expected to launch in Q1, 2014, if FDA approves them.
ZoomRx’s detailed study of the hemophilia market provides both quantitative and qualitative insights that cover the following topics:
- Current treatment trends
- Current product perception
- Unmet needs with current treatments
- Awareness and knowledge of in-development therapies
- Perception and anticipated use of Biogen Idec’s hemophilia drugs
- Barriers and drivers to the adoption of Biogen Idec’s hemophilia drugs
Hemophilia represents a group of congenital diseases that prevent individuals from adequately producing the coagulation factors needed to stop bleeding incidents. Without treatment, individuals with the disease can experience severe blood loss, permanent disability, or even death. There are approximately 20,000 people living with hemophilia in the United States, according to the US Centers for Disease Control and Prevention in 2013.
A deficiency of clotting factor VIII and factor IX result in hemophilia A and hemophilia B, respectively. Hemophilia has been treated since the late 1960s by replacing the clotting factor that patients produce insufficiently. Recombinant factors replaced plasma-derived factors in the early 1990s. Since then, similar recombinant factors from multiple manufacturers have been the dominant treatments, with few significant improvements.
Hemophilia patients, who follow a prophylactic treatment regimen, currently need a few infusions of the replacement factor every week, making the treatment inconvenient. In spite of this, hemophilia is not a dynamic market and patients exhibit high loyalty towards current therapies and a low willingness to switch across therapies. Further, the rarity of the disease leads to an inherently low influx of new patients.
ZoomRx is a privately-held, healthcare market research consultancy that specializes in primary and syndicated market research in various therapeutic specialties. ZoomRx tracking studies aim to deliver richer insights and higher RoI for their pharmaceutical and biotech clients through the use of innovative research methodologies and cutting-edge technology. ZoomRx’s feature-rich mobile technology platform is customized for the healthcare industry and is capable of generating both quantitative and qualitative insights.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
This press release contains opinions and forward looking statements that represent ZoomRx’s interpretation and analysis of information generally available to the public or reported by physicians professionally screened for the subject matter. ZoomRx believes that the sources of information on which the material is based are reliable. ZoomRx has also applied their best professional judgment to the data obtained. However, actual results could differ materially from those expressed, projected or implied in these forward-looking statements. ZoomRx cautions readers not to place undue reliance on such statements. ZoomRx does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. ZoomRx also does not assume any liability for the accuracy, comprehensiveness, or use of the information presented.